Researchers at Servizo Galego de Saude and Universidade de Santiago de Compostela have described senolytic compounds reported to be useful for the treatment of cancer, metabolic diseases, and neurological, dermatological, cardiovascular, eye, renal and inflammatory disorders.

Xylo Pty Ltd. has divulged 5-HT2A receptor agonists reported to be useful for the treatment of neurological and psychiatric disorders.

Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.

Merck KGaA has synthesized transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) and/or TAZ/TEAD interaction inhibitors reported to be useful for the treatment of cancer.

Researchers at Ehime University, Hamamatsu University School of Medicine and Shizuoka University have disclosed compounds reported to be useful for the treatment of hepatitis C virus (HCV) infections.

Pfizer Inc. has described acetyltransferase KAT2A and/or KAT2B inhibitors reported to be useful for the treatment of cancer.

Cascade Pharmaceuticals Inc. has divulged free fatty acid receptor 1 (FFAR1; GPR40) agonists reported to be useful for the treatment of diabetes.

Kestrel Therapeutics Inc. has identified GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

Euregen Biopharma Co. Ltd. has synthesized S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.

Researchers at Semmelweis University and University of Szeged have disclosed aminoalkylated benzoxy compounds acting as potassium channel blockers reported to be useful for the treatment of atrial fibrillation and ventricular arrhythmia.